Explore the published findings for tirzepatide, including Mounjaro and Zepbound.
36 cited sources120 recorded findingsStudy findings updated
AI-assisted research summary. These summaries are for general information. Read the original source for the full study and its limitations.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY-19.28%
Tirzepatide produced substantial weight loss in randomized trials
A randomized-trial network meta-analysis found 19.28% greater weight loss with tirzepatide than placebo. In an open-label randomized trial, weight change was -20.2% with tirzepatide versus -13.7% with semaglutide at 72 weeks.
The placebo comparison involved adults with overweight or obesity without diabetes; head-to-head evidence in that network was limited. The semaglutide comparison came from a phase 3b active-controlled trial.
See the evidence
Percentage weight loss with tirzepatide versus placebo among adults with overweight or obesity without diabetes in a network meta-analysis of randomized trials; head-to-head evidence was limited and residual uncertainty remained.
-19.28% 95% CI: -20.39% to -18.16%
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Mean weight change at 72 weeks with tirzepatide versus semaglutide in the included phase 3b open-label randomized active-controlled trial.
-20.2% vs -13.7%
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Tirzepatide lowered blood sugar more than dulaglutide
MD 0.67 percentage points
At week 24, tirzepatide 5 mg reduced the HbA1c blood-sugar measure by 0.67 percentage points more than dulaglutide 1.5 mg in a randomized-trial network meta-analysis.
The analysis involved people with type 2 diabetes, with or without established atherosclerotic cardiovascular disease. Several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
See the evidence
Dulaglutide 1.5 mg produced 0.67 percentage points less Week 24 HbA1c reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
MD 0.67 percentage points 95% CI: 0.25 to 1.09
Hageen, Ahmed W et al.. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.. Endocrinology, diabetes & metabolism. 2026.
Randomized evidence suggests fewer cardiovascular events and deaths
18%lower relative odds
In a network meta-analysis, tirzepatide had 18% lower relative odds of major cardiovascular events and 28% lower relative odds of all-cause death than placebo.
The evidence came from randomized trials of type 2 diabetes medicines lasting at least 40 weeks. These are relative odds, not absolute percentage-point differences.
See the evidence
18% lower relative odds, calculated from OR 0.82. This is not an absolute percentage-point difference.
MACE with tirzepatide versus placebo in the principal frequentist network meta-analysis of randomized trials lasting at least 40 weeks
OR 0.82 95% CI: 0.72-0.93
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
All-cause mortality with tirzepatide versus placebo in the principal frequentist network meta-analysis of randomized trials lasting at least 40 weeks
OR 0.72 95% CI: 0.64-0.82
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Hypotension increased, while heart-rhythm findings remained mixed
145%higher relative risk
Pooled randomized trials found a 145% higher relative risk of hypotension-related treatment-emergent adverse events with tirzepatide than pooled controls. Another meta-analysis found 84% higher odds of any arrhythmia versus placebo, but no clear atrial-fibrillation difference.
The hypotension analysis included people with type 2 diabetes or obesity; the summary does not identify its pooled control treatments. The rhythm analysis covered 10 trials in adults with overweight or obesity, and events were infrequent.
See the evidence
145% higher relative risk, calculated from RR 2.45. This is not an absolute percentage-point difference.
Hypotension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
RR 2.45 95% CI: 1.35-4.45
Chen, Qing-Xin et al.. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.. Endocrine. 2026.
Any arrhythmia with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; odds were higher, but event rates were low and the authors advised cautious interpretation.
OR 1.84 95% CrI: 1.04-3.90
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Atrial fibrillation with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; no significant association was found.
OR 2.20 95% CrI: 0.81-6.75
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Weight regain was estimated after semaglutide or tirzepatide stopped
1.04 kg/month
Across pooled semaglutide and tirzepatide studies, estimated regain was 1.04 kg/month after stopping. A model projected 50% of initial loss regained by 7.50 months.
Observed follow-up was 4-52 weeks. The timing estimate was model-based, and pooling both medicines prevents a tirzepatide-specific estimate.
See the evidence
Estimated post-discontinuation weight-regain rate across pooled semaglutide and tirzepatide studies
1.04 kg/month 95% CrI: 0.80-1.29 kg/month
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Linear-model projection for regaining 50% of initial weight loss after semaglutide or tirzepatide discontinuation; observed follow-up was 4-52 weeks, and longer-term estimates were model-based extrapolations
7.50 months 95% CrI: 5.05-10.57 months
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Tirzepatide improved obstructive sleep apnea in phase 3 trials
20-24 events/hour reduction
Tirzepatide reduced the apnea-hypopnea index by 20-24 events/hour versus placebo; 42%-50% met the trials' remission definition.
A review summarized SURMOUNT-OSA. A separate post hoc report described its two 52-week phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity receiving maximum-tolerated-dose tirzepatide. Remission meant an index below 5 events/hour, or below 15 without symptoms.
See the evidence
AHI reduction with tirzepatide versus placebo in the SURMOUNT-OSA phase 3 trials
20-24 events/hour reduction
Harris, Alexandria et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.. JAMA otolaryngology-- head & neck surgery. 2026.
Patients experiencing OSA disease remission with tirzepatide in the SURMOUNT-OSA phase 3 trials, defined as AHI below 5 events/hour or below 15 without symptoms
42%-50%
Harris, Alexandria et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.. JAMA otolaryngology-- head & neck surgery. 2026.
Descriptive, hypothesis-generating post hoc analyses of two 52-week phase 3 trials among adults with moderate-to-severe OSA and obesity receiving maximum-tolerated-dose tirzepatide; these are subgroup ranges rather than formal interaction-test results.
AHI reductions by baseline subgroup: age, -27.7 to -34.1 events/h; sex, -19.8 to -32.6 events/h; AHI severity, -12.1 to -52.2 events/h; BMI, -25.2 to -34.4 events/h; neck circumference, -23.9 to -30.8 events/h
Falcon, Beverly et al.. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2026.
Randomized trial weight loss favored tirzepatide over semaglutide
-20.2% vs -13.7%
In an open-label randomized active-controlled trial, mean weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide.
Real-world cohorts also favored tirzepatide by approximately 2.3-4.4 percentage points, but heterogeneity prevented pooling and four cohorts had serious risk of bias, principally from unadjusted confounding.
Study details & original results
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Mean weight change at 72 weeks with tirzepatide versus semaglutide in the included phase 3b open-label randomized active-controlled trial.
-20.2% vs -13.7%
Adjusted weight-reduction advantage favoring tirzepatide over semaglutide in real-world cohorts; substantial heterogeneity precluded meta-analysis, and four cohorts were judged at serious risk of bias, principally because of unadjusted confounding.
There were 47 tirzepatide suicide or self-injury reports among 42,941 eligible European pharmacovigilance reports; semaglutide and liraglutide had higher reporting disproportionality than tirzepatide.
These were spontaneous reports from 2021 through 2025, not incidence data. Reporting biases apply, and the findings do not establish causality.
Study details & original results
Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.
Reported suicide/self-injury cases among 42,941 eligible EudraVigilance reports from 2021 through 2025. These are spontaneous-report counts, not incidence estimates, and do not establish causality.
Reporting frequency of suicide/self-injury events with semaglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
ROR 2.69 95% CI: 1.91-3.83
Reporting frequency of suicide/self-injury events with liraglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
Weight-loss meta-analysis favored tirzepatide over semaglutide after surgery
4.23% greater mean total weight loss
At 6 months, the meta-analysis favored tirzepatide over semaglutide by 4.23% in mean total weight loss.
The meta-analysis included adults treated at least one year after metabolic bariatric surgery. Substantial heterogeneity across studies requires cautious interpretation.
Study details & original results
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
At 6 months, tirzepatide was favored over semaglutide for total weight loss among adults treated at least one year after metabolic bariatric surgery; the authors cautioned that substantial heterogeneity across studies requires cautious interpretation.
Tirzepatide was associated with fewer bowel-disease interventions
14%lower relative hazard
Compared with glucagon-like peptide-1 receptor agonists, tirzepatide was associated with a 14% lower relative hazard of the combined outcome of intravenous steroid use and intestinal surgery.
This propensity-matched study followed adults with inflammatory bowel disease for 18 months; it cannot establish that tirzepatide caused the difference.
Study details & original results
Patel, Krishan S et al.. Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.. Intestinal research. 2026.
Risk of the composite outcome of intravenous steroid use and intestinal surgery over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
aHR 0.86 95% CI: 0.73-0.97
Risk of intravenous steroid use over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
aHR 0.81 95% CI: 0.68-0.94
14% lower relative hazard, calculated from aHR 0.86. This is not an absolute percentage-point difference.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 120 findingsOriginal results, comparisons and study details.
36 of 36 source groupsFindings stay together with their study.
SOURCE 362 findings
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Adjusted weight-reduction advantage favoring tirzepatide over semaglutide in real-world cohorts; substantial heterogeneity precluded meta-analysis, and four cohorts were judged at serious risk of bias, principally because of unadjusted confounding.
Added
Approximately 2.3-4.4 percentage pointsSource [36]
SOURCE 353 findings
Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.
Reported suicide/self-injury cases among 42,941 eligible EudraVigilance reports from 2021 through 2025. These are spontaneous-report counts, not incidence estimates, and do not establish causality.
Reporting frequency of suicide/self-injury events with liraglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
Reporting frequency of suicide/self-injury events with semaglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
At 6 months, tirzepatide was favored over semaglutide for total weight loss among adults treated at least one year after metabolic bariatric surgery; the authors cautioned that substantial heterogeneity across studies requires cautious interpretation.
Patel, Krishan S et al.. Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.. Intestinal research. 2026.
Risk of intravenous steroid use over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
Risk of the composite outcome of intravenous steroid use and intestinal surgery over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
Risk of intravenous steroid use with tirzepatide versus GLP-1 receptor agonists in the ulcerative colitis subgroup of the propensity-matched observational study.
Hageen, Ahmed W et al.. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.. Endocrinology, diabetes & metabolism. 2026.
Tirzepatide 1 mg produced 4.39 kg less Week 16 body-weight reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, one trial contributed most participants, and significant inconsistency was observed for early body-weight outcomes.
Dulaglutide 0.75 mg produced 3.10 kg less Week 16 body-weight reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, one trial contributed most participants, and significant inconsistency was observed for early body-weight outcomes.
Additional Week 24 HbA1c reduction with tirzepatide 15 mg versus 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed 13,165 of 14,348 participants.
Added
MD -0.40 percentage points95% CI: -0.62 to -0.19Source [30]
Additional Week 24 HbA1c reduction with tirzepatide 10 mg versus 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
Added
MD -0.23 percentage points95% CI: -0.44 to -0.02Source [30]
Dulaglutide 1.5 mg produced 0.67 percentage points less Week 24 HbA1c reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
Added
MD 0.67 percentage points95% CI: 0.25 to 1.09Source [30]
SOURCE 314 findings
Liao, Kuang-Ming et al.. Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.. Frontiers in endocrinology. 2026.
No statistically significant difference in acute asthma exacerbation risk between tirzepatide and SGLT2 inhibitors among propensity-score-matched adults with asthma and type 2 diabetes (P = .064)
No statistically significant difference in acute asthma exacerbation risk between tirzepatide and GLP-1 receptor agonists among propensity-score-matched adults with asthma and type 2 diabetes (P = .49)
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Atrial fibrillation with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; no significant association was found.
Atrial arrhythmia with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; no significant association was found.
Any arrhythmia with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; odds were higher, but event rates were low and the authors advised cautious interpretation.
Patients experiencing OSA disease remission with tirzepatide in the SURMOUNT-OSA phase 3 trials, defined as AHI below 5 events/hour or below 15 without symptoms
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Percentage weight loss with tirzepatide versus placebo among adults with overweight or obesity without diabetes in a network meta-analysis of randomized trials; head-to-head evidence was limited and residual uncertainty remained.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Adults with overweight or obesity without diabetes receiving tirzepatide in an updated systematic review of RCTs; this was reported as an “up to” estimate, and heterogeneity precluded quantitative synthesis.
Added
-19.0% placebo-subtracted weight loss95% CI: -21.6% to -16.4%Source [25]
SOURCE 264 findings
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Linear-model projection for regaining 50% of initial weight loss after semaglutide or tirzepatide discontinuation; observed follow-up was 4-52 weeks, and longer-term estimates were model-based extrapolations
Linear-model projection for return to baseline weight after semaglutide or tirzepatide discontinuation; observed follow-up was 4-52 weeks, and longer-term estimates were model-based extrapolations
Falcon, Beverly et al.. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2026.
Descriptive, hypothesis-generating post hoc analyses of two 52-week phase 3 trials among adults with moderate-to-severe OSA and obesity receiving maximum-tolerated-dose tirzepatide; these are subgroup ranges rather than formal interaction-test results.
Added
AHI reductions by baseline subgroup: age, -27.7 to -34.1 events/h; sex, -19.8 to -32.6 events/h; AHI severity, -12.1 to -52.2 events/h; BMI, -25.2 to -34.4 events/h; neck circumference, -23.9 to -30.8 events/hSource [27]
SOURCE 241 finding
Galindo, Rodolfo J et al.. Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.. Journal of the Endocrine Society. 2026.
Tirzepatide-associated reduction in new-onset type 2 diabetes versus placebo among adults with obesity and prediabetes in the 3-year SURMOUNT-1 post hoc analysis, using high-risk and standard-risk classifications based on three exploratory glycemia criteria; the abstract reported ranges only and no interaction test.
Added
90%-99% reduction in high-risk groups; 68%-91% reduction in standard-risk groupsSource [24]
SOURCE 232 findings
Upadhyay, Navneet et al.. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.. Diabetes, obesity & metabolism. 2026.
Difference-in-differences estimate for all-cause healthcare costs, excluding tirzepatide, during months 12-18 among adults older than 55 years without type 2 diabetes initiating tirzepatide versus propensity-score-matched untreated controls.
Added
DiD -$319 per person per month (25.4% reduction; p=0.015)95% CI: -$544 to -$94Source [23]
Incidence of inpatient/emergency department visits during months 12-18 with tirzepatide versus matched untreated controls.
Clift, Ashley Kieran et al.. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.. Journal of the Endocrine Society. 2026.
Mean weight change at 10 months among tirzepatide-treated women with self-reported PCOS versus women without PCOS; the difference was not statistically significant, with only 40 women with PCOS reaching this time point.
Added
-19.40% vs -18.74%PCOS: 95% CI: -22.38% to -16.42%; without PCOS: 95% CI: -19.67% to -17.81%Source [22]
Kaplan-Meier-estimated proportion of tirzepatide-treated women with self-reported PCOS attaining at least 20% total body weight loss by 10 months.
Observational association between greater digital engagement and additional absolute weight loss by 10 months among tirzepatide-treated women with self-reported PCOS; P < .001.
Added
3.42% more weight loss95% CI: 1.71%-5.12%Source [22]
SOURCE 204 findings
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in propensity-matched adults with overweight or obesity and type 2 diabetes over a median follow-up of approximately 17 months; estimated incidence rates were 4.05 versus 4.04 per 1000 person-years, with no significant difference.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide among the subgroup with MASLD; incidence rates were 9.97 versus 10.03 per 1000 person-years, consistent with the primary analysis.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the as-treated sensitivity analysis, consistent with the primary analysis.
Greater BMI reduction with tirzepatide than with injectable semaglutide in the observational target-trial emulation.
Added
Mean BMI difference approximately 1.1 kg/m²; p<0.001Source [20]
SOURCE 215 findings
Xu, Ying et al.. Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.. Diabetes research and clinical practice. 2025.
Change from baseline to endpoint in HbA1c with tirzepatide 15 mg versus placebo in a Bayesian network meta-analysis of once-weekly agents.
Added
MD -1.4%Reported interval: -1.6% to -1.2%; interval type and level not specified in the abstractSource [21]
Greater weight loss with tirzepatide 15 mg versus other once-weekly GLP-1RAs in the Bayesian network meta-analysis; the abstract did not report the units.
Added
MD -8.7; units not specified in the abstractReported interval: -10 to -6.8; interval type and level not specified in the abstractSource [21]
All 5 findings from this source
Greater systolic blood-pressure reduction with tirzepatide 15 mg versus other once-weekly GLP-1RAs in the Bayesian network meta-analysis; the abstract did not report the units.
Added
MD -4.8; units not specified in the abstractReported interval: -8.2 to -1.4; interval type and level not specified in the abstractSource [21]
Higher nausea risk reported for tirzepatide 15 mg in the Bayesian network comparison; the abstract does not separately identify the odds ratio's reference treatment.
Added
OR 6.4Reported interval: 4.3-9.6; interval type and level not specified in the abstractSource [21]
Higher diarrhea risk reported for tirzepatide 15 mg in the Bayesian network comparison; the abstract does not separately identify the odds ratio's reference treatment.
Added
OR 3.5Reported interval: 2.5-5.2; interval type and level not specified in the abstractSource [21]
SOURCE 195 findings
Loblundo, Cali et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2026.
Apnea-hypopnea index with pooled liraglutide or tirzepatide versus controls in obstructive sleep apnea; the authors reported that the effect was independent of continuous positive airway pressure use.
Added
Mean difference -12.4 events/hour; P<.0000195% CI: -17.2 to -7.7Source [19]
Body-weight change with pooled liraglutide or tirzepatide versus controls among patients with obstructive sleep apnea.
Hypertension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
Hypotension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
Sattar, Naveed et al.. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.. PloS one. 2026.
Across-trial range for tirzepatide versus placebo achieving the triple endpoint of at least 5% body weight reduction, at least 5 mmHg systolic blood pressure reduction, and non-HDL-C below 130 mg/dL at the primary endpoint of each SURMOUNT trial.
Statistical significance of the between-treatment odds ratios for the triple-endpoint proportions across the SURMOUNT trials; numerical odds ratios were not provided in the abstract.
Gibble, Theresa Hunter et al.. Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.. Diabetes, obesity & metabolism. 2026.
Persistence during 6 months after tirzepatide initiation among 22,512 commercially insured US adults with obesity or overweight and without type 2 diabetes
Su, Yu-Jung et al.. Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.. Clinical pharmacology and therapeutics. 2026.
Khalil, Ibrahim et al.. Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.. Clinical cardiology. 2026.
Sattar, Naveed et al.. Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.. European journal of preventive cardiology. 2026.
Week 72 change from baseline in Framingham-predicted 10-year CVD risk with tirzepatide 15 mg versus placebo in the post hoc SURMOUNT-1 primary-prevention analysis; these were predicted risks, not observed cardiovascular events.
Added
Tirzepatide ARR -1.92% vs placebo ARI 1.10%; p<0.001Source [15]
Model-derived treatment-effect HR for Framingham-predicted 10-year CVD risk at week 72 with tirzepatide 15 mg versus placebo; this was not an HR based on observed cardiovascular events.
Week 176 change from baseline in Framingham-predicted 10-year CVD risk among tirzepatide-treated participants versus placebo in the post hoc SURMOUNT-1 primary-prevention analysis; these were predicted risks, not observed cardiovascular events.
Added
Tirzepatide ARR -1.31% vs placebo ARI 3.84%; p<0.001Source [15]
Model-derived treatment-effect HR for Framingham-predicted 10-year CVD risk at week 176 with tirzepatide versus placebo; this was not an HR based on observed cardiovascular events.
Rosenior-Patten, Onayomi et al.. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.. Diabetes, obesity & metabolism. 2026.
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Mean percentage body weight regain after tirzepatide cessation in the drug-class subgroup meta-analysis (k = 3); overall heterogeneity was high (I² = 97.6%).
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Adjusted relative likelihood of achieving at least 15% weight loss with tirzepatide versus liraglutide among adults with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
Mean weight change at 12 months among tirzepatide initiators with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
Mortada, Ibrahim et al.. Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.. Journal of the Society for Cardiovascular Angiography & Interventions. 2026.
Kamrul-Hasan, A B M et al.. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Tirzepatide 15 mg or maximum tolerated dose in adults with obesity without diabetes
Added
18.04% greater reduction in body weight versus placebo; p<0.0000195% CI: -19.86 to -16.22Source [6]
Exploratory indirect comparison of percentage weight loss across Asian and predominantly non-Asian trial populations; the analysis cannot establish equivalence
Added
-18.16% in Asian trials versus -17.92% in predominantly non-Asian trials; p=0.94Source [6]
SOURCE 077 findings
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Zeng, Lijuan et al.. Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.. Annals of the American Thoracic Society. 2026.
Wu, Jheng-Yan et al.. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. Journal of the American Heart Association. 2026.
Kahkedjian, Fredy et al.. Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.. Frontiers in endocrinology. 2026.
Kitsunai, Hiroya et al.. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.. Endocrine journal. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Browse the 36 original sourcesThe full bibliography behind this monitor.
[1]
Kitsunai, Hiroya et al.. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.. Endocrine journal. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Kahkedjian, Fredy et al.. Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.. Frontiers in endocrinology. 2026.
Wu, Jheng-Yan et al.. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. Journal of the American Heart Association. 2026.
Zeng, Lijuan et al.. Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.. Annals of the American Thoracic Society. 2026.
Kamrul-Hasan, A B M et al.. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Mortada, Ibrahim et al.. Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.. Journal of the Society for Cardiovascular Angiography & Interventions. 2026.
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Rosenior-Patten, Onayomi et al.. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.. Diabetes, obesity & metabolism. 2026.
Su, Yu-Jung et al.. Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.. Clinical pharmacology and therapeutics. 2026.
Khalil, Ibrahim et al.. Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.. Clinical cardiology. 2026.
Sattar, Naveed et al.. Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.. European journal of preventive cardiology. 2026.
Gibble, Theresa Hunter et al.. Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.. Diabetes, obesity & metabolism. 2026.
Sattar, Naveed et al.. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.. PloS one. 2026.
Loblundo, Cali et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2026.
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
Xu, Ying et al.. Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.. Diabetes research and clinical practice. 2025.
Clift, Ashley Kieran et al.. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.. Journal of the Endocrine Society. 2026.
Upadhyay, Navneet et al.. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.. Diabetes, obesity & metabolism. 2026.
Galindo, Rodolfo J et al.. Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.. Journal of the Endocrine Society. 2026.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Falcon, Beverly et al.. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2026.
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Hageen, Ahmed W et al.. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.. Endocrinology, diabetes & metabolism. 2026.
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Patel, Krishan S et al.. Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.. Intestinal research. 2026.
Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Study findings are generated with AI assistance and have not been reviewed by a clinician. The date on each finding records when it was added to this monitor; it is not the publication date or a clinical review date.
This monitor does not offer individual treatment advice. Bring personal health questions to a qualified clinician.
Get a summary twice a month when this evidence changes
A short summary twice a month, when validated evidence on this topic changes. If nothing changed, we don't email. No marketing. Subscribing covers GLP-1 receptor agonists, including its related monitor pages.
We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in GLP-1 receptor agonists; we treat that as sensitive: we store only your email address, this topic and the date you subscribed, never linked to any health record, and never sold. Temporary abuse counters use keyed identifiers and expire within 24 hours. Our email provider delivers the messages. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).